Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
FORT MILL, S.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a leading U.S.-based medical device company focusing on advanced solutions in the cardiac electrophysiology market, is proud to announce that its VIVO™ system has successfully secured a significant tender at Albert Szent-Györgyi Health Centre (Szeged University Hospital) in Hungary. This achievement marks Catheter Precision's inaugural installation in Hungary and reinforces its commitment to growth across Central and Eastern Europe. The tender was awarded in partnership with Fototronic, a well-established local distributor. Installation of the VIVO system is anticipated in the first quarter of 2026.
FORT MILL, S.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on the cardiac electrophysiology marketplace, today reported its results of operations for the quarter and nine months ended September 30, 2025. Highlights of the quarter and nine months include: Financial Highlights Total revenue reported for Q3 2025 was $226,000, an increase of 135% compared with $96,000 in Q3 2024.Total revenue was $581,000 for the nine months ended September 30, 2025, compared with $271,000 for the nine months ended September 30, 2024, an increase of 114%.GAAP net loss for Q3 2025 was $2,251,000, a 45% reduction compared to $
FORT MILL, S.C., June 12, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, is issuing this press release in response to recent increases in trading activity in its common stock. The Company is not aware of any information related to the Company or its operations that it would have expected to cause increased market activity. The Company continues to pursue its strategic plans as previously disclosed, including its ongoing efforts to secure financing to meet its liquidity needs. CONTACTS: At the CompanyDavid [email protected] # # #
8-K - Catheter Precision, Inc. (0001716621) (Filer)
8-K - Catheter Precision, Inc. (0001716621) (Filer)
10-Q - Catheter Precision, Inc. (0001716621) (Filer)
4 - Catheter Precision, Inc. (0001716621) (Issuer)
4 - Catheter Precision, Inc. (0001716621) (Issuer)
4 - Catheter Precision, Inc. (0001716621) (Issuer)
FORT MILL, SC / ACCESSWIRE / January 7, 2025 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced that it has brought on board Philip Anderson, to take on the position of Chief Financial Officer. Margrit Thomassen, who has been our Interim Chief Financial Officer, will continue with the company in the role of Controller.David Jenkins, CEO of Catheter Precision, commented on the hire, "After some time of searching for the right fit, we are happy to have concluded our search with Phil Anderson joining the team. His background includes executive management across a variety of industries, managing hedge fund
FORT MILL, SC / ACCESSWIRE / January 22, 2024 / Catheter Precision, Inc. (NYSE:VTAK), (the Company) a pioneering U.S. based medical device company committed to enhancing the well-being of patients with cardiac arrhythmias, is pleased to declare its participation in the forthcoming Sequire Investor Summit 2024. The eagerly awaited event, slated for January 23-25, 2024, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico, is poised to provide a spectrum of compelling opportunities for funds, companies, and investors.Puerto Rico has become a hub for family offices, funds, and affluent investors, thanks to its advantageous tax benefits. It stands out as one of the rare locations globally wh
FORT MILL, S.C., May 14, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending March 31, 2025. Highlights of the first quarter include: Commercial Endeavors Approximately 50 hospitals are currently in the process of evaluating either VIVO, LockeT or both devices demonstrating that our new sales team continues to build a strong pipeline.After the close of the March quarter, the Company announced its acquisition of the assets of Cardionomics, Inc. through its newly formed, 82% owned subsidiary, Cardionomix, Inc. Th
FORT MILL, S.C., March 28, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending December 31, 2024. Highlights of 2024 and the fourth quarter include: New Chief Commercial Officer (CCO) joined in Q2, 2024.Replaced the majority of our prior sales team with new salespeople selected by our new CCO and our CEO. Training was completed in Q3, 2024.The first sales of LockeT occurred in Q2 2024 and grew sequentially each quarter through the end of the year, to both new and repeat customers.The number of hospitals, inclu
FORT MILL, SC / ACCESSWIRE / November 13, 2024 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending September 30, 2024.Highlights of the third quarter include:Commercial EndeavorsMarie-Claude Jaques, our new Chief Commercial Officer, has now completed her first full quarter of engagement with the company, along with many of the new sales and clinical persons brought on board midway through the second quarter.The company now has 87 hospitals, including ambulatory surgical centers, in its pipeline of potential customers who have expressed i
SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)
SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)
SC 13D/A - Catheter Precision, Inc. (0001716621) (Subject)